[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abortion-missed\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abortion-missed":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100563413",false,"NCT06615843","Randomized Study of a Dematerialized Management for Post-Emergency Gynecological Follow-Up","GYNAB","Inclusion Criteria:\n\n* Women aged 18 and 60 years\n* No consultation at the gynecological emergency department in the previous month and\u002For for the same pregnancy.\n* Requires post-emergency follow-up for one of the following clinical conditions:\n\n  * Genital Infections (IGH): Acute pelvic pain with or without leucorrhea requiring antibiotic treatment\n  * Ectopic Pregnancy (GEU): Non-complicated, not ruptured, no significant effusion on ultrasound, GEU \\&amp;lt; 4 cm, no cardiac activity if embryo present, stable hemodynamic state, HCG \\&amp;lt; 5000, compliant patient, no contraindications for Methotrexate\n  * Early Pregnancy of Uncertain Viability (GLI): Early stage with a positive bHCG test, no visible gestational sac on ultrasound, no effusion, bHCG \\&amp;lt; 1500 IU\n  * Missed Miscarriage (GAM): Confirmed by an intrauterine gestational sac ≥ 25mm without an embryo or an intrauterine gestational sac with an embryo ≥ 7mm without visible cardiac activity, treated with Misoprostol\n  * First Trimester Bleeding (MTRt1): Moderate vaginal bleeding with an ongoing intrauterine pregnancy without hemodynamic instability\n  * Hyperemesis Gravidarum (VG): Severe vomiting before 12 weeks of pregnancy without severe criteria necessitating emergency follow-up\n\nExclusion Criteria:\n\n* Severe clinical intolerance, defined by:\n\n  * Signs of severe sepsis with unstable hemodynamics (TA with SBP \\\u003C 90 mmHg and FC ≥ 105 bpm)\n  * Abdominal defense or contracture\n  * Pain not controlled by level 1 analgesics (EVA \\\u003C7)\n  * Severe dehydration defined by a body weight loss of more than 10%\n  * Total food intolerance due to vomiting necessitating hospitalization\n  * Uncontrolled active hemorrhage\n* Significant ultrasound findings:\n\n  * Tubo-ovarian abscess ≥ 3 cm\n  * Significant intra-abdominal effusion\n* Non-French speaking patients\n* Inability to download or use the digital application due to precarious or isolated digital circumstances\n* Refusal to sign consent form\n* Patients under legal guardianship or court protection (tutelage, curatorship, or guardianship)\n* Patients not affiliated with a social security system","FEMALE","18 Years","60 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The GYNAB study aims to compare patient satisfaction and clinical outcomes between dematerialized post-emergency gynecological follow-up using a connected health app and traditional in-person follow-up. Conducted by Drs. Laëtitia CAMPIN and Louis MARCELLIN at Hôpital Cochin, it is sponsored by Assistance Publique - Hôpitaux de Paris. The main objective is to assess patient satisfaction at day 7 on a scale from 0 to 10, considering symptom management, follow-up quality, and task performance. Secondary objectives include comparing satisfaction at day 28, PROM-ED scores for symptom relief, understanding, reassurance, and care planning at days 7 and 28, hospitalization rates, unscheduled consultations, surgical interventions, total hospital time by day 28, and physician satisfaction at 28 days. This randomized trial involves women aged 18-60 needing follow-up for conditions like genital infections, non-complicated ectopic pregnancies, unlocated pregnancy, first trimester metrorrhagia, miscarriages , and severe vomiting before 12 weeks. Inclusion criteria are women aged 18-60 needing specified follow-up. Exclusion criteria are severe clinical intolerance, severe criteria ultrasound findings, non-French speakers, and inability to use digital applications. The intervention group uses a connected health app for data collection and communication, logging symptoms and test results, with medical team notifications for urgent updates. The control group receives traditional in-person follow-up with scheduled consultations and emergency contact information. The study hypothesizes that digital follow-up will improve patient experience, reduce hospital visits, and provide comparable or superior satisfaction and clinical outcomes. The results could promote broader digital health adoption in various medical fields.",[26,27,28,29,30],"Genital Diseases, Female","Ectopic Pregnancy","Uncertain Viability of Pregnancy","Abortion, Missed","Hyperemesis Gravidarum",[32,33,34,35,36,37,38],"Gynecological Emergencies","Post-Emergency Follow-Up","Patient-Reported Outcome Measures (PROMs)","Digital Health","Patient satisfaction","Telehealth","Asynchronous Medical Follow-up","RECRUITING","2026-04-20",{"date":42,"type":43},"2026-04-21","ACTUAL",{"date":45,"type":43},"2025-06-30",{"date":47,"type":20},"2027-07-30",{"name":49,"class":50},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":53,"slug":4,"hasResults":10,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":10,"sex":15,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100610668","NCT07230574","Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure","A Prospective, Multicenter, Randomized Controlled Clinical Study on Autologous Decidual-like NK Cells Therapy for Reproductive Failure Associated With Abnormal Uterine Natural Killer Cells","Inclusion Criteria:\n\n* Reproductive failure with abnormal endometrial natural killer (NK) cells in menstrual blood;\n* With a clear intention to conceive;\n* Normal ovarian function, or premature ovarian insufficiency with ≥2 high-quality cryopreserved embryos available for transfer;\n* Endometrial thickness measured by transvaginal ultrasound during the periovulatory period ≥7 mm;\n* Body mass index (BMI) between 18 kg\u002Fm² and 28 kg\u002Fm²;\n* Willing to comply with the follow-up plan of this study.\n\nExclusion Criteria:\n\n* Use of progesterone receptor modulators;\n* One of the couple's chromosomal karyotype abnormalities, with no euploid embryo identified via preimplantation genetic testing for aneuploidy;\n* Severe endometriosis or adenomyosis, uterine fibroids affecting uterine cavity morphology, uterine malformations, intrauterine adhesions, or thin endometrium;\n* Uncontrolled autoimmune or endocrine disorders;\n* Contraindications to pregnancy;\n* History of malignant tumors;\n* Participating in other clinical studies;\n* Allergy to blood products.","22 Years","38 Years",{"count":61,"type":20},159,[63],"PHASE2","The aim of this study is to verify the efficacy of in vitro induction of autologous decidual-like NK cells therapy for reproductive failure associated with uterine NK cells abnormalities.",[29,66,67],"Infertility Unexplained","Reproductive Disorder",[69,70,71,72],"Recurrent Pregnancy Loss","Repeated Implantation Failure","Unexplained Infertility","Decidual Natural Killer Cells","NOT_YET_RECRUITING","2025-11-13",{"date":76,"type":43},"2025-11-17",{"date":78,"type":20},"2025-11",{"date":80,"type":20},"2028-09",{"name":82,"class":50},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",""]